Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acorda Therapeutics Inc Completes Acquisition Of two neuropathic pain management assets from NeurogesX, Inc-Form 8-K


Tuesday, 9 Jul 2013 07:30am EDT 

On July 8, 2013 Acorda Therapeutics Inc (Acorda) reported in its Form 8-K that it has completed the acquisition of two neuropathic pain management assets from NeurogesX, Inc. (NeurogesX), including: Qutenza, which is approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia; and NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998. Acorda made an approximately $8 million payment to acquire development and commercialization rights for Qutenza and NP-1998 in the United States, Canada, Latin America and certain other territories, including $7 million paid to NeurogesX and approximately $900,000 for certain assumed accounts payable. Acorda will also make up to $5 million in payments contingent upon the achievement of certain regulatory and sales milestones related to NP-1998. 

Company Quote

33.12
 --
24 Apr 2015